HC Wainwright & Co. Reiterates Buy on Pliant Therapeutics, Maintains $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Ed Arce has reiterated a 'Buy' rating on Pliant Therapeutics (NASDAQ:PLRX) and maintained a $50 price target.
August 29, 2023 | 10:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Pliant Therapeutics (NASDAQ:PLRX) has had its 'Buy' rating reiterated by HC Wainwright & Co., with a maintained price target of $50.
The reiteration of a 'Buy' rating and a maintained price target of $50 by HC Wainwright & Co. is a positive signal for Pliant Therapeutics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100